NCT00284687View on ClinicalTrials.gov

Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Cytomegalovirus Infections
Interventions
DRUG

Artesunate

PO Artesunate

Trial Locations (1)

91120

Hadassah Medical Organization, Jerusalem

All Listed Sponsors
collaborator

Institut für Klinische und Molekulare Virologie

UNKNOWN

collaborator

University of Erlangen-Nürnberg Medical School

OTHER

lead

Hadassah Medical Organization

OTHER

NCT00284687 - Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients | Biotech Hunter | Biotech Hunter